Art. -Nr.: HY-107025

Cf1743

Name: Cf1743
Brand: MedChemExpress
SKU: HY-107025
Price: 45.00 USD
Availability: InStock
Rating: 5 (1 reviews)

Kundenbewertung

Based on 1 Customer Validation

Cf1743 is a potent anti-varicella-zoster virus (VZV) bicyclic nucleoside analogue. Cf1743 has antiviral activity, with an IC₅₀ of 3.3 μM for VZV thymidine kinase (TK).

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.44%
CAS. Nr.: 319425-66-6
Formel: C₂₂H₂₆N₂O₅
Molecular Weight:398.45

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Cf1743 Chemical Structure

CAS. Nr.: 319425-66-6

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Cf1743 is a potent anti-varicella-zoster virus (VZV) bicyclic nucleoside analogue. Cf1743 has antiviral activity, with an IC₅₀ of 3.3 μM for VZV thymidine kinase (TK)^[1].

Cellular Effect

Cell Line	Type	Value	Description	References
HEL	CC₅₀	>200 μM Compound: 4f	cytostatic concentration required to reduce the HEL cell number by 50%. after 5 days in the absence of virus cytostatic concentration required to reduce the HEL cell number by 50%. after 5 days in the absence of virus	[PMID: 11150169]
HEL	EC₅₀	>20 μM Compound: 4f	Evaluated for the anti-VZV, the concentration of compounds in uM required to reduce VZVTK-07 ( thymidine kinase-deficient strain ) plaque formation after 5 days in HEL cell cultures compared to untreated controls. Evaluated for the anti-VZV, the concentration of compounds in uM required to reduce VZVTK-07 ( thymidine kinase-deficient strain ) plaque formation after 5 days in HEL cell cultures compared to untreated controls.	[PMID: 11150169]
HEL	EC₅₀	>5 μM Compound: 4f	Evaluated for the anti-VZV, the concentration of compounds in uM required to reduce VZVTK-YS-R ( thymidine kinase-deficient strain ) plaque formation after 5 days in HEL cell cultures compared to untreated controls. Evaluated for the anti-VZV, the concentration of compounds in uM required to reduce VZVTK-YS-R ( thymidine kinase-deficient strain ) plaque formation after 5 days in HEL cell cultures compared to untreated controls.	[PMID: 11150169]
HEL	EC₅₀	0.0001 μM Compound: 4f	Evaluated for the anti-VZV activity, the concentration of compounds in uM required to reduce VZV TS plaque formation after 5 days in HEL cell cultures compared to untreated controls. Evaluated for the anti-VZV activity, the concentration of compounds in uM required to reduce VZV TS plaque formation after 5 days in HEL cell cultures compared to untreated controls.	[PMID: 11150169]
HEL	EC₅₀	0.0003 μM Compound: 4f	Evaluated for the anti-VZV activity, the concentration of compounds in uM required to reduce VZV OKA Plaque formation after 5 days in HEL cell cultures compared to untreated controls. Evaluated for the anti-VZV activity, the concentration of compounds in uM required to reduce VZV OKA Plaque formation after 5 days in HEL cell cultures compared to untreated controls.	[PMID: 11150169]
HEL	EC₅₀	0.1 nM Compound: 4f	Evaluated for the anti-VZV activity, the concentration of compounds in uM required to reduce VZV TS plaque formation after 5 days in HEL cell cultures compared to untreated controls. Evaluated for the anti-VZV activity, the concentration of compounds in uM required to reduce VZV TS plaque formation after 5 days in HEL cell cultures compared to untreated controls.	[PMID: 11150169]
HEL	EC₅₀	0.3 nM Compound: 4f	Evaluated for the anti-VZV activity, the concentration of compounds in uM required to reduce VZV OKA Plaque formation after 5 days in HEL cell cultures compared to untreated controls. Evaluated for the anti-VZV activity, the concentration of compounds in uM required to reduce VZV OKA Plaque formation after 5 days in HEL cell cultures compared to untreated controls.	[PMID: 11150169]
HEL	CC₅₀	>200 μM Compound: f	Cytotoxic activity against cultured human embryonic lung (HEL) cells Cytotoxic activity against cultured human embryonic lung (HEL) cells	[PMID: 16392824]
HEL	CC₅₀	>50 μM Compound: 4	Cytotoxicity against HEL cells after 3 days Cytotoxicity against HEL cells after 3 days	[PMID: 17622128]
HEL	EC₅₀	>0.5 μM Compound: 4	Antiviral activity against thymidine kinase deficient VZV YS/R in HEL cells assessed as reduction of virus plaque formation after 5 days Antiviral activity against thymidine kinase deficient VZV YS/R in HEL cells assessed as reduction of virus plaque formation after 5 days	[PMID: 17622128]
HEL	EC₅₀	>1.3 μM Compound: 4	Antiviral activity against thymidine kinase deficient VZV 07/1 in HEL cells assessed as reduction of virus plaque formation after 5 days Antiviral activity against thymidine kinase deficient VZV 07/1 in HEL cells assessed as reduction of virus plaque formation after 5 days	[PMID: 17622128]
HEL	EC₅₀	>10 μM Compound: 4	Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation after 7 days Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation after 7 days	[PMID: 17622128]
HEL	EC₅₀	>10 μM Compound: 4	Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation after 7 days Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation after 7 days	[PMID: 17622128]
HEL	EC₅₀	0.001 μM Compound: 4	Antiviral activity against TK+ VZV YS in HEL cells assessed as reduction of virus plaque formation after 5 days Antiviral activity against TK+ VZV YS in HEL cells assessed as reduction of virus plaque formation after 5 days	[PMID: 17622128]
HEL	EC₅₀	0.004 μM Compound: 4	Antiviral activity against TK+ VZV OKA in HEL cells assessed as reduction of virus plaque formation after 5 days Antiviral activity against TK+ VZV OKA in HEL cells assessed as reduction of virus plaque formation after 5 days	[PMID: 17622128]
HEL	CC₅₀	>50 μM Compound: 1, BCNA	Cytotoxicity against HEL cells Cytotoxicity against HEL cells	[PMID: 18052321]
HEL	EC₅₀	>5 μM Compound: 1, BCNA	Antiviral activity against TK- VZV 07 in HEL cells after 5 days Antiviral activity against TK- VZV 07 in HEL cells after 5 days	[PMID: 18052321]
HEL	EC₅₀	>5 μM Compound: 1, BCNA	Antiviral activity against TK- VZV YS in HEL cells after 5 days Antiviral activity against TK- VZV YS in HEL cells after 5 days	[PMID: 18052321]
HEL	EC₅₀	0.0001 μM Compound: 1, BCNA	Antiviral activity against TK+ VZV YS in HEL cells after 5 days Antiviral activity against TK+ VZV YS in HEL cells after 5 days	[PMID: 18052321]
HEL	EC₅₀	0.0003 μM Compound: 1, BCNA	Antiviral activity against TK+ VZV OKA in HEL cells after 5 days Antiviral activity against TK+ VZV OKA in HEL cells after 5 days	[PMID: 18052321]
HEL	EC₅₀	0.1 nM Compound: 1, BCNA	Antiviral activity against TK+ VZV YS in HEL cells after 5 days Antiviral activity against TK+ VZV YS in HEL cells after 5 days	[PMID: 18052321]
HEL	EC₅₀	0.3 nM Compound: 1, BCNA	Antiviral activity against TK+ VZV OKA in HEL cells after 5 days Antiviral activity against TK+ VZV OKA in HEL cells after 5 days	[PMID: 18052321]
HEL	CC₅₀	>200 μM Compound: 3	Cytotoxicity against human HEL cells Cytotoxicity against human HEL cells	[PMID: 19328697]
HEL	EC₅₀	0.0005 μM Compound: 3	Antiviral activity against Varicella Zoster virus YS infected in HEL cells assessed as reduction in viral plaque formation after 5 days Antiviral activity against Varicella Zoster virus YS infected in HEL cells assessed as reduction in viral plaque formation after 5 days	[PMID: 19328697]
HEL	EC₅₀	0.0006 μM Compound: 3	Antiviral activity against Varicella Zoster virus Oka infected in HEL cells assessed as reduction in viral plaque formation after 5 days Antiviral activity against Varicella Zoster virus Oka infected in HEL cells assessed as reduction in viral plaque formation after 5 days	[PMID: 19328697]
HEL	EC₅₀	0.5 nM Compound: 3	Antiviral activity against Varicella Zoster virus YS infected in HEL cells assessed as reduction in viral plaque formation after 5 days Antiviral activity against Varicella Zoster virus YS infected in HEL cells assessed as reduction in viral plaque formation after 5 days	[PMID: 19328697]
HEL	EC₅₀	0.6 nM Compound: 3	Antiviral activity against Varicella Zoster virus Oka infected in HEL cells assessed as reduction in viral plaque formation after 5 days Antiviral activity against Varicella Zoster virus Oka infected in HEL cells assessed as reduction in viral plaque formation after 5 days	[PMID: 19328697]
HEL	EC₅₀	>20 μM Compound: 1, BCNA	Antiviral activity against thymidine kinase deficient Varicella zoster virus 07/1 infected human HEL cells assessed as reduction in viral plaque formation after 5 days Antiviral activity against thymidine kinase deficient Varicella zoster virus 07/1 infected human HEL cells assessed as reduction in viral plaque formation after 5 days	[PMID: 19833513]
HEL	EC₅₀	0.0097 μM Compound: 1, BCNA	Antiviral activity against Varicella zoster virus OKA infected human HEL cells assessed as reduction in viral plaque formation after 5 days Antiviral activity against Varicella zoster virus OKA infected human HEL cells assessed as reduction in viral plaque formation after 5 days	[PMID: 19833513]
HEL	CC₅₀	>=100 μM Compound: 1, Cf1743	Cytotoxicity against HEL cells assessed as inhibition of cell proliferation Cytotoxicity against HEL cells assessed as inhibition of cell proliferation	[PMID: 21332170]
HEL	EC₅₀	0.003 μM Compound: 1, Cf1743	Antiviral activity against Varicella zoster virus OKA infected in HEL cells assessed as reduction in virus induced cytopathicity Antiviral activity against Varicella zoster virus OKA infected in HEL cells assessed as reduction in virus induced cytopathicity	[PMID: 21332170]
HEL	EC₅₀	0.004 μM Compound: 1, Cf1743	Antiviral activity against Varicella zoster virus YS infected in HEL cells assessed as reduction in virus induced cytopathicity Antiviral activity against Varicella zoster virus YS infected in HEL cells assessed as reduction in virus induced cytopathicity	[PMID: 21332170]
HEL	EC₅₀	>20 μM Compound: 12, BCNA	Antiviral activity against acyclovir-resistant thymidine kinase-deficient Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against acyclovir-resistant thymidine kinase-deficient Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 24177359]
HEL	EC₅₀	>20 μM Compound: 12, BCNA	Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 24177359]
HEL	EC₅₀	>20 μM Compound: 12, BCNA	Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 24177359]
HeLa	CC₅₀	>200 μM Compound: 2	Cytotoxic concentration required to inhibit Hel cell growth Cytotoxic concentration required to inhibit Hel cell growth	[PMID: 15109620]
HeLa	CC₅₀	>200 μM Compound: 4	Cytotoxic concentration required to inhibit Hel cell growth by using DMSO as solvent Cytotoxic concentration required to inhibit Hel cell growth by using DMSO as solvent	[PMID: 15993062]

Chemical Information

CAS. Nr. 319425-66-6
Appearance Solid
Molecular Weight 398.45
Formel C₂₂H₂₆N₂O₅
Color White to off-white
SMILES

O=C1N=C2C(C=C(C3=CC=C(C=C3)CCCCC)O2)=CN1[C@@H](C[C@@H]4O)O[C@@H]4CO
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (265 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. McGuigan C, et al. 2'-Fluorosugar analogues of the highly potent anti-varicella-zoster virus bicyclic nucleoside analogue (BCNA) Cf 1743. Bioorg Med Chem Lett. 2009 Nov 15;19(22):6264-7. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge: